➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Express Scripts
Moodys
Baxter
Merck

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for MGL-3196

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for MGL-3196?

MGL-3196 is an investigational drug.

There have been 12 clinical trials for MGL-3196. The most recent clinical trial was a Phase 1 trial, which was initiated on September 15th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Madrigal Pharmaceuticals, Inc., Celerion, and Worldwide Clinical Trials.

There are six US patents protecting this investigational drug and ninety-eight international patents.

Recent Clinical Trials for MGL-3196
TitleSponsorPhase
A Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) PatientsMadrigal Pharmaceuticals, Inc.Phase 3
Drug Interaction Study of MGL-3196 With ClopidogrelMadrigal Pharmaceuticals, Inc.Phase 1
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisMadrigal Pharmaceuticals, Inc.Phase 3

See all MGL-3196 clinical trials

Clinical Trial Summary for MGL-3196

Top disease conditions for MGL-3196
Top clinical trial sponsors for MGL-3196

See all MGL-3196 clinical trials

US Patents for MGL-3196

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MGL-3196   Start Trial Methods of synthesizing thyroid hormone analogs and polymorphs thereof Madrigal Pharmaceuticals, Inc. (West Conshohocken, PA) Hoffmann-La Roche Inc. (Little Falls, NJ)   Start Trial
MGL-3196   Start Trial Thyroid hormone analogs Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
MGL-3196   Start Trial Thyroid hormone analogs Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
MGL-3196   Start Trial Prodrugs of thyroid hormone analogs Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
MGL-3196   Start Trial Method of synthesizing thyroid hormone analogs and polymorphs thereof Madrigal Pharmaceuticals, Inc. (Fort Washington, PA) Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MGL-3196

Drugname Country Document Number Estimated Expiration Related US Patent
MGL-3196 Argentina AR092872 2032-09-17   Start Trial
MGL-3196 Australia AU2013315017 2032-09-17   Start Trial
MGL-3196 Brazil BR112015005891 2032-09-17   Start Trial
MGL-3196 Canada CA2884481 2032-09-17   Start Trial
MGL-3196 Canada CA3090070 2032-09-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Express Scripts
Moodys
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.